Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of MRG002 versus trastuzumab emtansine in HER2-positive unresectable locally advanced or metastatic breast cancer
CTR20211204Phase 3Active
- Sponsor
- Hangzhou Miracogen
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MRG002 in breast cancer, sponsored by Hangzhou Miracogen. Started Jul 2021; status: active.
02
Drugs
MRG002
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20211204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211204.